Janssen Announces U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative

In the Phase 3 pivotal trial, more than 40 percent of patients receiving STELARA subcutaneous (SC) injections every 8 weeks were in clinical remission at one year and not taking corticosteroidsSTELARA is the first and only approved treatment for ulcerative colitis to demonstrate improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement endpoint
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news